Drug Treatment
20/07/2012 23:49
1: Angeli F, Reboldi G, Mazzotta G, Garofoli M, Cerasa MF, Verdecchia P. Statins
in acute coronary syndrome: very early initiation and benefits. Ther Adv
Cardiovasc Dis. 2012 Jul 11. [Epub ahead of print] PubMed PMID: 22789992.
2: Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P. Safety and
efficacy of aliskiren in the treatment of hypertension: a systematic overview.
Expert Opin Drug Saf. 2012 Jul;11(4):659-70. PubMed PMID: 22724663.
3: Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E,
Biadetti A, Verdecchia P. Safety and efficacy of aliskiren in the treatment of
hypertension and associated clinical conditions. Curr Drug Saf. 2012 Feb
1;7(1):76-85. PubMed PMID: 22663961.
4: Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence
for cardiovascular, cerebrovascular, and renal protective effects of
renin-angiotensin system blockers. Ther Adv Cardiovasc Dis. 2012 Apr;6(2):81-91.
Epub 2012 Apr 23. PubMed PMID: 22528743.
5: Angeli F, Reboldi G, Garofoli M, Ramundo E, Verdecchia P. Very early
initiation of statin therapy and mortality in patients with acute coronary
syndrome. Acute Card Care. 2012 Mar;14(1):34-9. Epub 2012 Feb 1. Review. PubMed
PMID: 22295883.
6: Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Blood
pressure lowering in diabetic patients. J Hypertens. 2012 Feb;30(2):438-9. PubMed
PMID: 22236979.
7: Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood
pressure control in diabetes: evidence-based review of treatment targets in
patients with diabetes. Curr Cardiol Rep. 2012 Feb;14(1):89-96. Review. PubMed
PMID: 22139528.
8: Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the
reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol.
2011 Mar;4(2):151-61. PubMed PMID: 22115399.
9: Angeli F, Reboldi G, Verdecchia P. Lowering blood pressure with β-blockers in
peripheral artery disease: the importance of comorbidity. J Hypertens. 2011
Jul;29(7):1298-302. PubMed PMID: 21659823.
10: Angeli F, Reboldi G, Verdecchia P. Good news for β-blockers in perioperative
medicine. Expert Opin Drug Saf. 2011 Jul;10(4):491-8. Epub 2011 May 24. PubMed
PMID: 21609193.
11: Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment
of hypertension. Diabetes Care. 2011 May;34 Suppl 2:S313-9. Review. PubMed PMID:
21525475.
12: Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects
of intensive blood pressure reduction on myocardial infarction and stroke in
diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011
Jul;29(7):1253-69. PubMed PMID: 21505352.
13: Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk:
still a HOPE for ACE inhibitors? Expert Opin Pharmacother. 2011 Apr;12(6):839-43.
Epub 2011 Feb 16. PubMed PMID: 21323501.
14: Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive
subjects with diabetes mellitus. Curr Atheroscler Rep. 2011 Apr;13(2):176-85.
Review. PubMed PMID: 21234720.
15: Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G.
ß-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery.
Am J Cardiovasc Drugs. 2010;10(4):247-59. doi: 10.2165/11539510-000000000-00000.
PubMed PMID: 20653331.
16: Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin
converting enzyme inhibitors and angiotensin receptor blockers in the treatment
of hypertension: should they be used together? Curr Vasc Pharmacol. 2010
Nov;8(6):742-6. PubMed PMID: 20626343.
17: Verdecchia P, Angeli F, Mazzotta G, Reboldi G. Is hydrochlorothiazide more
effective on LVH in nonresponders to losartan than in those to atenolol? Am J
Hypertens. 2010 Jul;23(7):705. PubMed PMID: 20559290.
18: Angeli F, Reboldi G, Verdecchia P. "The lower the BP the better" paradigm in
the elderly: vanished by VALISH? Hypertension. 2010 Aug;56(2):182-4. Epub 2010
Jun 7. PubMed PMID: 20530297.
19: Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Garofoli M, Martire P,
Reboldi G. The optimal blood pressure target for patients with coronary artery
disease. Curr Cardiol Rep. 2010 Jul;12(4):302-6. Review. PubMed PMID: 20425161.
20: Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence
of blood pressure reduction on composite cardiovascular endpoints in clinical
trials. J Hypertens. 2010 Jul;28(7):1356-65. PubMed PMID: 20375907.
21: Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Repaci S, del Pinto M,
Gentile G, Cavallini C, Reboldi G. Beta-blockers and risk of all-cause mortality
in non-cardiac surgery. Ther Adv Cardiovasc Dis. 2010 Apr;4(2):109-18. Epub 2010
Mar 3. Review. PubMed PMID: 20200201.
22: Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin
receptor blockers in hypertension. New insights from Japan. Hypertens Res. 2010
May;33(5):394-7. Epub 2010 Feb 12. Review. PubMed PMID: 20150909.
23: Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G.
Comparative assessment of angiotensin receptor blockers in different clinical
settings. Vasc Health Risk Manag. 2009;5:939-48. Epub 2009 Nov 16. Review. PubMed
PMID: 19997575; PubMed Central PMCID: PMC2788599.
24: Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal
combination therapy in hypertensive patients with diabetes mellitus. Expert Rev
Cardiovasc Ther. 2009 Nov;7(11):1349-61. Review. PubMed PMID: 19900018.
25: Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor
combinations in hypertensive patients with type 2 diabetes: update after recent
clinical trials. Vasc Health Risk Manag. 2009;5(1):411-27. Review. PubMed PMID:
19475778; PubMed Central PMCID: PMC2686259.
26: Angeli F, Verdecchia P, Del Pinto M, Cavallini C, Reboldi G. Perioperative
beta blockade: the debate continues. Lancet. 2009 Feb 21;373(9664):627; author
reply 628. PubMed PMID: 19231621.
27: Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA,
Reboldi G. Blood pressure reduction and renin-angiotensin system inhibition for
prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009
Mar;30(6):679-88. Epub 2009 Jan 23. PubMed PMID: 19168534.
28: Rolfo F, Bobbio M, Angeli F, Cavallini C. [The POISE study]. G Ital Cardiol
(Rome). 2008 Dec;9(12):803-7. Review. Italian. PubMed PMID: 19119689.
29: Angeli F, Gentile G, Reboldi G, Verdecchia P. Angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers and protection from stroke. Expert Rev
Cardiovasc Ther. 2008 Oct;6(9):1171-4. PubMed PMID: 18939903.
30: Verdecchia P, Gentile G, Angeli F, Reboldi G. Should we prefer different
drugs to treat hypertension in older and younger adults? Practical implications
of clinical trials: European perspective. Pol Arch Med Wewn. 2008
Sep;118(9):513-6. Review. PubMed PMID: 18846987.
31: Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers on the risk of myocardial infarction, stroke and death: a
meta-analysis. J Hypertens. 2008 Jul;26(7):1282-9. PubMed PMID: 18550998.
32: Cardio-Sis Study Group. Randomized study of traditional versus aggressive
systolic blood pressure control (Cardio-Sis): rationale, design and
characteristics of the study population. J Hum Hypertens. 2008 Apr;22(4):243-51.
Epub 2007 Nov 29. PubMed PMID: 18046432.
33: Verdecchia P, Angeli F, Achilli P, Castellani C, Repaci S, Ambrosio G.
[Beta-blockers and arterial hypertension. Evidence-based medicine or excessive
perseverance?]. G Ital Cardiol (Rome). 2007 Sep;8(9):552-8. Review. Italian.
PubMed PMID: 17972424.
34: Verdecchia P, Cavallini C, Angeli F, Andreani F, Garofoli M, Reboldi GP,
Ambrosio G. [Antihypertensive therapy and cardiovascular prevention. The role of
angiotensin II receptor blockers]. G Ital Cardiol (Rome). 2007 Aug;8(8):491-7.
Review. Italian. PubMed PMID: 17695700.
35: Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive
treatment, and outcome. Hypertension. 2007 Sep;50(3):459-60. Epub 2007 Aug 6.
PubMed PMID: 17679646.
36: Verdecchia P, Angeli F, Reboldi G, Gattobigio R. Is the development of
diabetes with antihypertensive therapy a problem?--Pro. J Clin Hypertens
(Greenwich). 2006 Feb;8(2):120-6. Review. PubMed PMID: 16470081.
37: Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor
blockers increase the risk of myocardial infarction? Eur Heart J. 2005
Nov;26(22):2381-6. Epub 2005 Aug 4. PubMed PMID: 16081468.
38: Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L,
Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium
channel blockers for coronary heart disease and stroke prevention. Hypertension.
2005 Aug;46(2):386-92. Epub 2005 Jul 11. PubMed PMID: 16009786.
39: Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA,
Porcellati C. Calcium channel blockade to prevent stroke in hypertension: a
meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004
Sep;17(9):817-22. PubMed PMID: 15363825.
40: Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in
patients with hypertension, heart failure, or both. Clin Ther. 2004
Apr;26(4):460-72. Review. PubMed PMID: 15189744.
41: Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA,
Porcellati C. Meta-Analysis of effectiveness or lack thereof of
angiotensin-converting enzyme inhibitors for prevention of heart failure in
patients with systemic hypertension. Am J Cardiol. 2004 Jan 15;93(2):240-3.
PubMed PMID: 14715360.
42: Verdecchia P, Angeli F. [The Seventh Report of the Joint National Committee
on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure:
the weapons are ready]. Rev Esp Cardiol. 2003 Sep;56(9):843-7. Review. Spanish.
PubMed PMID: 14519269.
———
Back